|
Basic Characteristics of Mutations
|
|
Mutation Site
|
A181T |
|
Mutation Site Sentence
|
The most commonly detected mutation was M204VI (9 cases) and M250VI (11 cases), which were resistant to lamivudine and entecavir, and entecavir, respectively. Other mutations resistant to adefovir were detected in 7 (50.0%) and 3 (21.4%) cases at A181TV and N236T, respectively (Table 4). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
B;C |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B, Chronic
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
Abacavir(ADV) |
|
Location
|
Japan |
|
Literature Information
|
|
PMID
|
22523569
|
|
Title
|
Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing
|
|
Author
|
Nishijima N,Marusawa H,Ueda Y,Takahashi K,Nasu A,Osaki Y,Kou T,Yazumi S,Fujiwara T,Tsuchiya S,Shimizu K,Uemoto S,Chiba T
|
|
Journal
|
PloS one
|
|
Journal Info
|
2012;7(4):e35052
|
|
Abstract
|
BACKGROUND AND AIMS: Although the advent of ultra-deep sequencing technology allows for the analysis of heretofore-undetectable minor viral mutants, a limited amount of information is currently available regarding the clinical implications of hepatitis B virus (HBV) genomic heterogeneity. METHODS: To characterize the HBV genetic heterogeneity in association with anti-viral therapy, we performed ultra-deep sequencing of full-genome HBV in the liver and serum of 19 patients with chronic viral infection, including 14 therapy-naive and 5 nucleos(t)ide analogue(NA)-treated cases. RESULTS: Most genomic changes observed in viral variants were single base substitutions and were widely distributed throughout the HBV genome. Four of eight (50%) chronic therapy-naive HBeAg-negative patients showed a relatively low prevalence of the G1896A pre-core (pre-C) mutant in the liver tissues, suggesting that other mutations were involved in their HBeAg seroconversion. Interestingly, liver tissues in 4 of 5 (80%) of the chronic NA-treated anti-HBe-positive cases had extremely low levels of the G1896A pre-C mutant (0.0%, 0.0%, 0.1%, and 1.1%), suggesting the high sensitivity of the G1896A pre-C mutant to NA. Moreover, various abundances of clones resistant to NA were common in both the liver and serum of treatment-naive patients, and the proportion of M204VI mutants resistant to lamivudine and entecavir expanded in response to entecavir treatment in the serum of 35.7% (5/14) of patients, suggesting the putative risk of developing drug resistance to NA. CONCLUSION: Our findings illustrate the strong advantage of deep sequencing on viral genome as a tool for dissecting the pathophysiology of HBV infection.
|
|
Sequence Data
|
DRA000435
|
|
|